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ABSTRACT 
 
IDENTIFICATION OF MicroRNAs INVOLVED IN CAMPTOTHECIN-
INDUCED APOPTOSIS IN JURKAT T CELL LINE 
 
MicroRNAs which are non-coding RNAs 19-25 nt in length regulate gene 
expression at post-transcriptional and translational stages. Although it is known that 
they play a role in critical processes such as development and differentiation of T cells, 
a major component of the immune system, the function of miRNAs in T cell apoptosis 
is unknown. This study has aimed to identify miRNAs’ involvement in camptothecin-
induced T cell apoptosis in the  Jurkat T cell leukemia cell line model. Following the 
enrichment of the apoptotic population by magnetic seperation, the negative and 
apoptotic fractions were profilled and compared according to the expression levels of 
microRNAs. Out of the 866 miRNAs in the miRBASE, 37 and 58 of them were down- 
and up-regulated in the apoptotic fraction, respectively. 7 miRNAs were members of the 
clusters that have predicted targets as anti-apoptotic genes and tumour suppressor 
proteins. 66 miRNAs have no known function. Candidate miRNAs, selected based on 
their higher differential expression levels with predicted apoptotic/antiapoptotic targets, 
will be verified by qPCR. These candidate then will be further characterized by 
overxpression and knock-down studies.  
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ÖZET 
 
JURKAT T HÜCRE HATTINDA KAMPTOTESİN İLE İNDÜKLENMİŞ 
APOPTOZDA ROL OYNAYAN MikroRNALARIN TANIMLANMASI 
 
Post-transkripsiyonel ve translasyonel aşamada gen regulasyonunu 
gerçekleştiren, kodlamaya katılmayan ve 19-25 nükleotid uzunluğa sahip miRNA’ların, 
immun sistemin önemli bileşenlerinden olan T hücrelerinin gelişimi ve farklılaşması 
gibi kritik proseslerde görev aldığı anlaşılmasına rağmen T hücrelerinin apoptozunda 
hangi miRNA’ların rol oynadığı bilinmemektedir. Bu çalışmada T hücre apoptozunda 
rol oynayan mikroRNAların belirlenmesi amaçlanmıştır.  Jurkat T hücresi lösemi 
hattının model olarak kullanıldığı bu çalışmada apoptoz indüksiyonu kamptotesin ile 
sağlanmış ve apoptotik populasyonun manyetik ayrım ile zenginleştirilmesi  sonrasında  
negatif  ve apoptotik fraksiyon mikroRNA array analizi ile ekspresyon seviyeleri 
bakımından profillenerek karşılaştırılmıştır. Tarama yapılan 866 miRNA arasından 37 
tanesinde ekspresyon seviyesinde azalma, 58 tanesinde artma gözlenmiştir. Literatür 
taraması sonucunda ekspresyon seviyesi bakımından fark gösteren 7 miRNAnın  
birlikte görev yapan ve tahminlenen hedefleri arasında antiapoptotik genler ve tumor 
baskılayıcı proteinler olduğu görülen grupların üyeleri olduğu ortaya çıkmıştır. 66 
tanesine literatürde rastlanamamıştır. Ekspresyon seviyeleri ve apoptozda rol oynadığı 
bilinen moleküllerin hedeflenme olasılığı göz önünde bulundurularak seçilen aday 
miRNAların qPCR ile doğrulaması yapıldıktan sonra overexpression ve knockdown 
çalışmaları ile apoptozdaki olası rolleri ortaya çıkarılmaya çalışılacaktır.  
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CHAPTER 1 
 
INTRODUCTION 
 
1.1. miRNAs: Biogenesis and Function 
 
MicroRNAs (miRNAs) are non-coding small RNAs of about 19-25 nucleotides 
in lenght that negatively regulate gene expression by translational inhibition or 
destabilization of mRNAs of protein coding genes by binding to complementary target 
sequences in 3’ untranslated region (UTR) (Stefani and Slack 2008, Miska 2005, 
Lawrie 2007). They were originally discovered in Caenorhabditis elegans as post-
transcriptional regulators of genes involved in developmental timing and are now 
known to have effects on gene expression in all multicellular eukaryotes (Nilsen 2007). 
miRNAs can be encoded in independent transcription units, in polycistronic clusters or 
within the introns of protein-coding genes (Stefani and Slack 2008). A single 
microRNA can target several hundred genes. It is estimated that between 10–30% of all 
human genes are a target for microRNA regulation (Lawrie 2007). A single target gene 
also contains putative binding sites for multiple microRNAs that can bind cooperatively 
and form complex regulatory control networks. 
miRNAs are generated from precursor molecules known as primary miRNAs 
(pri-miRNAs), which are transcribed from either intergenic or intronic transcripts by 
RNA polymerase II (Figure 1.1). Pri-miRNAs are cleaved by Drosha/DGCR8 complex 
in nucleus to form pre-miRNAs of about 70 nt hairpin structure (Filipowicz, et al. 2008; 
Stefani and Slack 2008). Following this cleavage pre-miRNAs are transported to 
cytoplasm by exportin-5 and processed into 19-25 nt mature miRNA duplex by Dicer. 
After helicase activity, one strand is selected to incorporate into functional RNA-
induced silencing complex (RISC) which contains miRNA, an Argonaute protein and 
other protein factors and is the effector complex of the miRNA pathway (Stefani and 
Slack 2008). The RISC is directed to mRNAs that are complementary to its miRNA 
component. The strand loaded into the complex prefentially has the lowest free energy 
at its 5’ terminus (Kloosterman, et al. 2006, Lawrie 2007).  
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Figure 1.1. miRNA biogenesis steps 
(Source: Lodish, et al. 2008) 
 
RISC inhibits mRNA expression in two ways, depending on the degree of 
complementarity between miRNA and the target. If there is a perfect match between 
target mRNA and miRNA, mostly in plants, the target mRNA is cleaved and degraded 
(Stefani and Slack 2008, Shyu, et al. 2008). Another mode of inhibition is translational 
repression, as in animals whose miRNAs generally show a lower degree of 
complementarity to their target (Filipowicz, et al. 2008, Yu, et al. 2007).  In animals 
miRNAs recognize their targets by interactions of seed region consisting of nucleotides 
2 to 7 in the 5’ terminus of miRNA and 3’ UTR of target mRNA (Neilson, et al. 2007, 
Kloosterman, et al. 2006). 
miRNAs have capacity to regulate many crucial developmental and 
physiological decisions such as developmental timing, differentiation, cell proliferation, 
organ development, maintenance of stem cell potency and apoptosis as well as many 
types of cancers (Nilsen 2007, Kloosterman, et al. 2006). 
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1.2 . Apoptosis  
 
1.2.1. Definition and Morphological Features 
 
Apoptosis is programmed cell death performed by activation of cysteine 
proteases known as caspases in a chain reaction manner triggered by various stimuli 
from outside or inside the cell such as ligation of cell surface receptors, treatment with 
cytotoxic drugs or irradiation (Blank and Shiloh 2007). It has a regulatory role in the 
development, the maintenance of tissue homeostasis and repair of tissues. Defects in 
this regulation results in pathological conditions such as developmental defects, 
autoimmune diseases, neurodegeneration or cancer (Jin and El-Deiry 2005, Blank and 
Shiloh 2007, Baumann, et al. 2002).  
Cells undergoing apoptosis show characteristic morphology, including exposure 
of phosphotidylserine on membrane surface, membrane blebbing, cellular shrinkage, 
chromatin condensation and fragmentation of nucleus leading to formation of apoptotic 
bodies (Figure 1.2) (Blagosklonny 2000, Blank and Shiloh 2007, Baumann, et al. 2002). 
 
 
(a) (b) 
 
 
 
 
 
 
 
 
    (a)    (b) 
Figure 1.2.  Morphological features of apoptosis. Trypan-blue staining of (a) Round-shaped live jurkat 
       cells with membrane integrity (b) Apoptotic jurkat cells with membrane blebbing and   
apoptotic body formation indicated with the arrows. 
 
1.2.2. Pathways of Apoptosis 
 
Apoptosis is induced via two main routes (Figure 1.3) involving either activation 
of death receptors (the extrinsic pathway) or mitochondria (the intrinsic pathway) 
(Taylor, et al. 2008, Kiechle and Zhang 2002). The extrinsic pathway involves binding 
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of extracellular ligands (e.g., FasL) to death receptors on cell surface which are 
members of tumour necrosis factor (TNF) receptor superfamily, including Fas, 
TRAMP, TNF receptor 1 and 2, TRAIL receptor 1 and 2 (Osthoff 1998, Blank and 
Shiloh 2007, Baumann, et al. 2002). As a result initiator caspases (caspase-8) and 
downstream effector caspases (caspases-3, 6, 7) are activated in a cascade effect that 
results in apoptosis (Blank and Shiloh 2007). 
In the intrinsic pathway, stress-induced apoptosis is initiated by release of 
protein cytochrome c from the inter-mitochondrial membrane space. Once released, 
cytochrome c triggers a caspase activating complex called apoptosome by binding its 
component, apoptotic protease-activating factor 1 (Apaf1) with caspase 9. Upon 
activation, effector caspase 3 is activated in a chain reaction manner (Blank and Shiloh 
2007, Taylor, et al. 2008). Cytochrome c release is regulated by Bcl2 family, composed 
of pro-apoptotic, anti-apoptotic and BH3-only members. As seen in Figure 1.3, Bid is a 
member of BH3-only protein family that promotes pro-apoptotic proteins Bax-Bak 
assembly and release of cytochrome c from mitochondrial intermembrane. On the other 
hand, antiapoptotic Bcl2 blocks apoptosis by preventing Bax-Bak assembly and pore 
formation (Taylor, et al. 2008, Baumann, et al. 2002).   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. Major pathways of apoptosis. As a result of receptor-ligand interaction or by effect of 
                  apoptotic stimuli, a cascade of events occur to result in apoptosis whereas regulator molecules 
                  also take place within (Source: Mak and Yeh 2002). 
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Apoptosis can also be induced by several reagents such as camptothecin, an 
antitumor extract of plant Camptotheca acuminata, which is a human topoisomerase I 
(TOP I) inhibitor (Li and Liu 2001, Pommier, et al. 2003). Topoisomerase I relaxes 
DNA supercoils by single strand breaks which allows DNA double helix to rotate 
around intact strand during transcription and chromatin replication (Figure 1.4). When 
DNA is relaxed, Topoisomerase I ligates strand breaks and regenerates double helix. 
Camptothecin specifically inhibits the religation step by interaction with topoisomerase 
I-DNA complex generating DNA strand breaks which trigger elevations in p53 protein 
levels (Nelson et al., 1994). The p53 tumor suppressor serves as a positive regulator of 
pro-apoptotic Bcl-2 family members such as Bax and BH3-only member Bid (Blank 
and Shiloh 2007, Li and Liu 2001, Pommier, et al 2003, Taylor, et al. 2008). p53 also 
functions by neutralizing anti-apoptotic proteins such as Bcl-xL and activating pro-
apoptotic regulators Bax or Bak to initiate mitochondrial outer membrane 
permeabilization. Followed by p53 activation cytochrome c is released from 
mitochondria; caspases are activated and results in DNA fragmentation (Sanchez, et al. 
2000).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. Topoisomerase I action on supercoiled DNA. TOP I introduces transient single strand nicks 
                  on DNA and enables rotation. DNA lesions and drugs such as camptothecin inhibits religation 
(Source: Pommier 2006). 
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The induction of mitochodrial membrane permeabilization also leads to the 
release of other pro-apoptotic molecules such as Smac (second mitochondrial activator 
of caspases)/Diablo (direct inhibitors of apoptosis binding protein with low pH) and 
Omi/HtrA2 (high temperature requirement factor) (Blank and Shiloh 2007). They can 
enhance apoptosis by inactivating IAPs, which function upon binding and inhibiting 
active forms of caspases. Overexpression of Smac/Diablo or Omi/HtrA2 in cells has 
been shown to markedly increase their sensitivity to apoptosis induction by DNA 
damage and other signals.  
Apoptosis plays a key role in regulation of immune system where one of the 
major components is T lymphocytes. Dysregulation of immune system causes immune-
related disorders such as autoimmune diseases and malignancies (Lodish, et al 2008). 
Studies revealed that homeostasis and function of immune system is maintained by 
growth factors, cell surface receptors, intracellular signaling molecules and transcription 
factors. Recent studies have introduced new mediators having role in post-
transcriptional regulation of gene expression in function and development of immune 
cells known as microRNAs (miRNAs). 
 
1.3. miRNA-Mediated Regulation of Apoptosis  
 
Due to homology between Drosophila and mammalian system (Figure 1.4), 
studies performed on Drosophila show that miRNAs are involved in apoptosis (Miska, 
2005). Drosophila caspase Drice, is a target of miR-14 which has antiapoptotic activity 
(Bergmann and Lane 2003). Hid, Reaper, Grim and Sickle proteins inhibit function of 
DIAP1 (inhibitor of apoptosis), cell death regulator (Jovanovic and Hartgarner 2006; 
Hwang and Mendell 2006). As Bantam negatively regulates Hid protein expression, 
members of miR-2 family, miR-2 and miR-13 are also thought to regulate proapoptotic 
genes hid, reaper, grim and sickle result in downregulation of apoptosis (Jovanovic and 
Hartgarner 2006; Wienholds and Plasterk 2005). 
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a)     b) 
 
 
 
 
 
 
Figure 1.5. Pathway of apoptosis in a) Drosophila and b) mammalian system  
(Source: Jovanovic, et al. 2006) 
 
In addition to studies performed on Drosophila, researchers focused on miRNA-
apoptosis relationship also by in vitro studies. Cheng et al. (2005) used an antisense 
RNA library to knock down 90 human miRNAs in HeLa (cervical carcinoma) and A549 
(lung carcinoma) cell lines, testing for changes in apoptosis. Caspase-3 level was 
measured as the indicator. It was found that inhibition of seven miRNAs (miR-1d, 7, 
148, 204, 210, 216 and 296) led to increased caspase-3 activity, suggesting potential 
role of miRNAs in apoptosis. 
Calin et al. (2003) identified miR-15a and miR-16-1 cluster in loss of 
chromosomal region 13q14 which is associated with B cell chronic lymphocytic 
leukemia (CLL) but no protein coding genes. Cimmino et al. (2005) showed that miR-
15a and miR-16-1 expression is indeed inversely correlated with Bcl2 expression in 
chronic lymphocytic leukemia (CLL) cells. Bcl2 is an antiapoptotic gene that blocks the 
mitochondrial release of cytochrome c and inhibits the activation of caspase 9 through 
sequences that are imperfectly complementary to the target mRNA, mainly to the 
3’UTR. The Bcl2 3’UTR region contains one potential binding site for both miRNAs. 
miRNA expression in cell lines with high Bcl2 levels caused a reduction in Bcl2 protein 
levels, without affecting Bcl2 mRNA levels, indicating that the regulation of expression 
is post-transcriptional.  
Cimmino et al. (2005) also reported that miR-15a/16-1 cluster induces apoptosis 
of human acute megakaryoblastic leukemia cell line, MEG-01 by activating the intrinsic 
apoptosis pathway as identified by activation of the APAF-1–caspase 9 pathway. Calin 
et al. (2008) investigated the mechanism of miR-15a and miR-16-1 as tumor 
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suppressors in leukemias by analyzing the transcriptome and proteome in MEG-01 
acute megakaryocytic leukemic cells. Tumour suppressor function was tested by in vitro 
transfection of nude mice with miR-15a/16-1- transfected MEG-01 cells and after 28 
days, tumour growth was completely suppressed in three of the five (60%) mice. 
Microarray analysis of MEG-01 cells transiently transfected with pRS15/16 vector 
containing the genomic region encoding both miRNAs showed that after transfection 
3,307 genes were down-regulated and 265 were up-regulated which of none were 
predicted as a target of miR-15a/16. MEG-01 cells transfected with pSR15/16 were also 
analyzed by proteomics analysis to investigate effects at the protein level and 27 
different proteins grouped in four according to functions as regulation of cell growth 
and cell cycle, antiapoptotic proteins, proteins involved in human tumorigenesis, as 
oncogenes, or as tumor-suppressor genes were isolated. 
Recent studies have also identified miR-34 family as a microRNA component of 
the p53 network (Hannon et al. 2007). As mentioned before, p53 is a transcription factor 
coordinating cellular responses to DNA damage and oncogene activation and altering 
expression of genes leading to cell-cycle arrest, apoptosis and increased DNA repair 
upon induction (Chang, et al. 2007). p53 may also regulate the expression of specific 
miRNAs. miRNA profiling of p53-proficient cells differs from cells lacking p53 (Xi et 
al., 2006).  
Relationship between p53 and miRNAs has been investigated using different 
profiling approaches. Chang et al. (2007) compared miRNA profiles of p53+/+ and p53-
/- HCT116 colon cancer cells in response to DNA damage. After treatment with 
adriamycin, a DNA-damaging agent, seven miRNAs, miR-23a, miR-26a, miR-34a, 
miR-30c, miR-103, miR-107, and miR-182 were found upregulated. Shapira et al. 
(2007) and Tarasov et al. (2007) probed miRNA levels in lung carcinoma cells (H1299). 
P53 null H1299 cells were transfected with temperature sensitive p53 mutant (H1299-
ts) that could express active p53 when the temperature shifted to 32oC. RNA from 
H1299 and H1299-ts cells was hybridized on array and elevated expression miRNAs 
638, 373*, 492, 126, 140, 491, and 296 was observed. miR-34a elevation was more than 
10-fold. 
The expression of miR-34a, miR-34b and miR-34c is induced by DNA damage 
in a p53-dependent manner. When overexpressed, miR-34 leads to apoptosis or cellular 
senescence, whereas reduction of miR-34 function attenuates p53-mediated cell death 
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showing that miRNAs can affect tumorigenesis by working within tumor suppressor 
pathways (Hannon, et al. 2007) 
The predicted targets of miR-34a also include mRNAs whose inhibition might 
mediate p53 functions. A mild decrease in Bcl2 protein upon miR-34a overexpression 
was also observed (Shapira, et al. 2007). It is possible that miR-34a can act together 
with other miRNAs such as miR-15 and miR-16 (Cimmino, et al. 2005) to suppress 
effectively Bcl2 protein levels.   
Studies on T lymphocytes have revealed miRNAs’ role in development and 
differentiation stages such as miR-150 and miR-146 in differentiation (Monticelli, et al. 
2005) and miR-155 (Neilson, et al. 2007) in regulatory T cell formation and function 
(Lodish, et al. 2008). Li et al. (2007) Although studies on miRNA expression relative to 
developmental stages reveal their role in establishing and/or maintaining cell identity in 
lymphocytes in stage specific manner; miRNAs that regulate apoptosis in T 
lymphocytes are unknown.  In this study it is aimed to identify and understand the 
function of miRNAs having role in T lymphocyte apoptosis. As miRNA expression 
differs according to development, activation and pathologic stages of an organism; 
deciphering changes in miRNA profile may have potential role in defining new 
pathogenic pathways and novel treatments. 
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CHAPTER 2 
 
MATERIALS AND METHODS 
 
2.1. Materials 
 
The human leukemic T cell line, Jurkat, was obtained from American Type 
Culture Collection (clone E6.1). Camptothecin was purchased from Sigma. Annexin V 
PE and 7AAD were provided from Becton Dickonson (BD). Cell separator, kits and 
columns were from Miltenyi Biotech. Kits used in total RNA isolation and DNase 
treatment were obtained from Ambion.  
 
2.2. Cell Culture  
 
Jurkat cell line, originated from human T cell leukemia, was maintained in 
RPMI 1640 (Gibco) supplemented with L-glutamine, 10% fetal bovine serum (GIBCO), 
2% penicillin-streptomycin (Biochrom AG) in an atmosphere of 5% CO2 at 37oC. Cells 
were passaged every 48 hours.  
Camptothecin dose and treatment time were optimized to capture cells at the 
early apoptotic stage. 106 cells were treated with camptothecin (Sigma–Aldrich) at three 
time points (16, 6 and 4 hours respectively) and concentrations between 0,5-1024 μM 
(Johnson et al., 1997). Camptothecin was dissolved in DMSO (Applichem) at a 
concentration of 10 mg/ml (28700 μM) as stock solution. Working concentrations were 
prepared by serial dilution in culture media composed of RPMI 1640 supplemented 
with 10% FBS. Cell culture was set up in a 500 μl volume. In culture setting 
camptothecin dilutions were added to the formerly distributed media. Lastly cells were 
distributed into culture tubes, vortexed for homogenization and incubated at 37oC, 5% 
CO2.   
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2.3. Immunoflorescent Labeling 
 
Apoptosis was measured by flow cytometry after labeling with Annexin V PE 
and 7AAD (BD Pharmingen). Phosphotidylserine layer of the cell membrane was 
flipped inside out in apoptotic cells providing binding site for annexin V. Upon 
apoptosis progression, membrane integrity was lost and 7AAD was bound to DNA as 
DNA was fragmented. Following treatment with camptothecin, culture media was 
removed by centrifugation at 1400 rpm, +4oC for 6 minutes. The supernatant was 
aspired by vacuum and cells were washed with 1XPBS (Gibco) and centrifuged as 
before. The pellet was re-suspended in 20 μL of Annexin-binding buffer (BD 
Pharmingen) followed by incubation with 10 μL Annexin V PE and 10 μL 7AAD (both 
diluted 1:5 in 1XPBS containing 0,1% NaN3) for 20 minutes at +4oC. Then, 300 μL of 
Annexin binding buffer was added to the samples and loaded on 96-well plates for 
analysis by flow cytometry (BD FacsArray). Cells were monitored in dot-blot and 
histogram graph. In dot blot analysis cells were distributed in four parts indicative of 
various stages of apoptosis. Early apoptotic annexin-positive, 7AAD-negative cells 
were distributed in Q1 part whereas double positive (annexin positive 7AAD positive) 
apoptotic cells in Q2. Q3 part showed annexin and 7AAD negative live population. 
Membrane integrity was completely distorted in late apoptotic population which was 
annexin negative 7AAD positive and monitored in Q4 part. Data analysis was 
performed by MS Excel. Optimum camptothecin concentration and time point was 
determined to collect early stage apoptotic jurkat T cells.  
 
2.4. Cell Sorting 
 
Apoptotic cells were seperated by VarioMacs magnetic cell seperation system 
composed of magnetic columns and Annexin V Microbead Kit (Miltenyi Biotech). The 
choice of column depended on the approximate number of annexin-positive cells. MS 
column was used up to 107 annexin-positive cells whereas LS column was used when 
there were 108 annexin-positive cells. The culture was set in large scale between 5-
7*107 cells as a starting number. Cells were treated with camptothecin at optimum 
concentration and incubation time determined by changing concentrations at fixed time 
points. Camptothecin treated and non-treated cells were collected and centrifuged at 
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300xg, at 9oC for 10 minutes. Cells were resuspanded in 1X Binding Buffer in 80 μl 
buffer/107 cells and incubated with Annexin V MicroBeads as 20 μl bead/107 cells for 
15 minutes at 9oC in dark. Following incubation, cells were washed with 1X binding 
buffer (2 ml buffer/107 cells) and the pellet was resuspended in 1X binding buffer. 
Buffer volume varied between 0,5-10 ml with the capacity of the column. The column 
was prepared by washing with 1X binding buffer. The annexin negative fraction was 
collected as the cell suspension was applied through the column. The column was 
washed four times with 1X binding buffer to collect the annexin-negative fraction 
completely. The annexin-positive population retained in column was passed through by 
21 G needle as the column was removed from the magnetic zone and washed with 1X 
binding buffer.  
Four group of cells have been obtained as two subfractions for each of treated 
and untreated population termed as annexin-positive and annexin-negative. The cells in 
each fraction were counted by trypan blue staining. 106 cells of each fraction were 
analysed in flow cytometry after immunoflorescent labeling with Annexin V PE and 
7AAD. Apoptosis percentage and distribution of cells in dot blot analysis of each 
fraction were used to assess the purity and efficiency of the sorting process.  
 
2.5. Sample Preparation 
 
2.5.1.  RNA Isolation 
 
Total RNA was isolated from apoptotic and non-apoptotic cells by mirVana 
miRNA isolation kit (Ambion). Sorted cells were pelleted at 1400 rpm, +4oC for 6 
minutes and washed with 1X PBS. Cell pellets were lysed by pipetting and vortexing 
with lysis buffer (300 μl/102-106 of cells, 600 μl/106 of cells). After incubation with 
homogenate additive for 10 minutes on ice, phenol-chloform extraction was performed. 
Phenol-chloroform was added as equal to lysate volume. The sample was then vortexed 
for 30-60 seconds and centrifuged at 10000xg, at room temperature for 5 minutes to 
separate organic and aqueous phases. Following centrifugation, aqueous phase 
containing RNA was transferred to a fresh tube and 1,25x volume of 100% ethanol at 
room temperature was added to the aqueous phase. Samples were passed through filters 
to retain nucleotides in washing steps by centrifuging at 10000xg, room temperature 
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according to manufacturer’s instructions and eluted in 100 μl pre-heated DEPC-treated 
water. RNA concentration, 260/280 and 260/230 ratios of the recovered RNA was 
measured by Nanodrop (NanoDrop® ND-1000). 
 
2.5.2. DNase Treatment and Quality Control 
 
Total RNA samples were treated with TurboDNase DNA-free kit (Ambion) to 
remove genomic DNA contamination. The reaction volume was fixed at 50 μl. 1 μl 
DNase and 5 μl 10X reaction buffer was used up to 10 μg RNA. Volume was completed 
to 50 μl by adding DEPC-treated water and reaction was incubated at 37oC for 30 
minutes. DNase was inactivated by the inactivation reagent included in the kit. 
Following incubation at room temperature for 2 minutes, the samples were centrifuged 
at 13000 rpm at room temperature and the aqueous phase containing DNA-free RNA 
was collected in a fresh tube without disturbing the interface.  
Concentration and purity of the samples were measured and compared with the 
untreated group by Nanodrop spectrophotometer. Absorbance ratio of 260 nm/280 nm 
and 260 nm/230 nm between 1,8-2,1 refers to RNA sample free of contaminants such as 
ethanol, phenol, thiocyanate and protein. RNA integrity was also checked by 
Bioanalyzer (Agilent 2100) using RNA 6000 Nano Kit. A RIN higher than 7 on a scale 
of 0-10 indicates RNA of good quality for the array analysis. 
 
2.6.  Microarray Analysis 
 
Samples sets for the array analysis included 2 replicates of annexin-negative 
fraction of negative control (JNN), 3 replicates of annexin positive (JAP) and negative 
fractions (JAN) of the camptothecin treated group. After fulfilling the quality control 
requirements with regard to the 260/280 and 260/230 ratios and RIN, 1 μg of each 
sample was aliquoted for the array analysis. The miRNA array analysis was conducted 
by Febit Biomed Gmbh, Germany.  
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CHAPTER 3 
 
RESULTS AND DISCUSSION 
 
3.1. Dose Response and Time Point Assay for Camptothecin-induced 
Apoptosis 
 
Camptothecin-induced apoptosis in Jurkat cell line was optimized in order to 
capture cells at the early apoptotic stage. First cells were exposed to camptothecin at 
concentrations between 0,5-8 μM for 16 hours. The flow cytometric analysis showed 
that 64% of cells were annexin positive. Concentrations higher than 0,5 μM did not 
show any significant difference during the 16 h time period (Figure 3.1) Dose 
dependence could not be observed in 0,5-8 μM camptothecin concentration range. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Camptothecin dose response graph for 16 hours between concentrations 0,5-8 μM. 64% of 
                  cells were annexin positive when treated with 0,5 μM camptothecin. Apoptosis percentage did 
                  not change significantly at concentrations higher than 0,5 μM. 
 
The camptothecin concentration was fine-tuned (0,025-2 μM) to observe a dose 
effect before reaching a plateu. The percentage of annexin-positive cells increased 
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proportionally up to 0,5 μM camptothecin. At higher concentrations, the dose-
dependence was lost. As seen in Figure 3.2, 63,7% of cells became annexin positive at 
0,5 μM concentration and no significant difference of dose effect was seen at higher 
concentrations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Camptothecin dose response for 16 h between concentrations 0,025-2 μM. Percentage of 
                  annexin-positive cells gradually increased up to 0,5 μM. Highest apoptotic percentage was 
                  63,7%. 
 
Dot blot analysis showed that cells passed to apoptotic region, Q2 in 16 h 
treatment as seen in Figure 3.3. To retain cells at the early apoptotic phase, the 
treatment time was reoptimized to 4 h. The concentration range was broadened from 0,5 
to 1024 μM to see the full plateu and the decrease of annexin-positive cells in dose 
response. Figure 3.4 shows that the highest apoptotic ratio was 41% at 8 μM 
camptothecin in 4 h and 37% of the apoptotic cells were at the early apoptotic phase as 
can be seen in Figure 3.3.b. In Figure 3.3.a it can also be seen that 63% of the cells were 
apoptotic treated with 0,5 μM camptothecin in 16 h and only 37% of the cells were at 
the apoptotic phase. Cells could be captured at early apoptotic phase in 4h treatment 
with 8 μM camptothecin.  
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(a)   (b) 
 
Figure 3.3. Dot blot analysis of dose response assay a) 16 h treatment with 0,5 μM camptothecin b) 4 h 
treatment with 8 μM camptothecin. Jurkat cells were labeled with Annexin PE and 7 AAD as 
explained in Materials and Methods. Annexin-positive cells distributed in Q1 part represents 
early apoptotic phase whereas annexin and 7AAD-positive cells in Q2 part are at apoptotic 
phase. 7AAD-positive cells in Q4 are at the late apoptotic phase. Q3 part shows live cells. 
Apoptosis percentage was 63,7% in 16 h treatment with 8 μM camptothecin and 37% of the 
apoptotic cells were at the early apoptotic phase. For 4 h treatment with 8 μM camptothecin, 
41% of the cells were apoptotic and 37% were at the early apoptotic phase.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Camptothecin dose response for 4 h. Cells were treated with camptothecin between 
concentrations 0,5-1024 μM to see the full plateu. Highest apoptotic percentage was 41% at 
8 μM camptothecin. After this point, dose dependence was lost. 
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3.2. Apoptotic Cell Sorting 
 
 Following optimization, cells were exposed to camptothecin in large scale up to 
60 million cells, incubated with 20 μl of Annexin V microbeads per 107 cells in order to 
sort apoptotic and non-apoptotic populations. Both negative control and camptothecin-
treated cells were sorted, each group had two subgroups within as annexin-negative and 
positive populations (Figure ). Samples were taken before and after sorting for flow 
cytometric analysis to identify apoptotic percentage in negative control, camptothecin-
treated population and sorted fractions. After sorting, camptothecin-treated population 
of 68% apoptotic was enriched by 89% in positive fraction. Dot blot analysis shows live 
and apoptotic population of fractions (Figure 3.5).  
 
Negative control
(Non-treated)
Camptothecin-treated 8 uM 4h
JNN (Jurkat negative
control negative fraction)
JNP (Jurkat negative
control positive fraction)
JAN (Jurkat apoptotic
negative fraction)
JAP (Jurkat apoptotic
positive fraction)
Incubation with AnnexinV microbeads and cell sorting
 
 
Figure 3.5. Apoptotic cell sorting. Non-treated and camptothecin-treated cells were incubated with 
                  Annexin V magnetic microbeads and sorted by magnetic columns. Each group have two 
                  subgroups as annexin-negative and positive fractions 
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Figure 3.6. Dot blot analysis of a) Negative fraction of negative control b) Positive fraction of 
camptothecin-treated population. Distribution of the cells determine purity of the fractions. 
Percentage of live cells in negative fraction of the negative control was 90%, distributed in 
Q3 part. 58% of the cells were apoptotic in camptothecin-treated group. After sorting 
apoptotic population was enriched to 97% as seen in (b). 
 
 
3.3. RNA isolation and DNase Treatment 
 
 Total RNA was isolated from cells by using mirVana miRNA isolation kit 
(Ambion). When samples were run on 1% agarose gel, genomic DNA bands were 
observed. DNA contamination was removed by TurboDNase (Ambion) to determine 
RNA concentration exactly. In Figure 3.6, gel photograph shows DNase treated and 
non-treated samples.  
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Figure 3.7. Gel photograph of DNase-treated and non-treated samples. Total RNA samples of 500 ng 
                  from each fraction were loaded on 1% agarose gel prepared in 0,5X TBE buffer 
                 (Tris/Borate/EDTA electrophoresis buffer). EtBr was added at the concentration of 0.5 µg/ ml 
                 from a 10 mg/ml stock. Samples were exposed to an electric constant at 80V for 30 min and 
                 visualized in gel documentation system. Genomic DNA was removed by DNase treatment.  
 
3.4.  RNA Quality Control 
 
 The RNA sample quality was determined by Nanodrop spectrophotometer and 
Bioanalyzer (Table 3.1). 260/280 and 260/230 ratio gave information about the purity 
whereas Bioanalyzer electropherograms represent the integrity of the samples generated 
by the ratio of 18S and 28S ribosomal subunits. RIN higher than 7 refers to RNA of 
good quality. The extent of degredation increases as RIN decreases. 
 
 Quality of DNase-treated and non-treated samples were controlled and 
compared by Bioanalyzer. As seen in Figure 3.8a and b change in RNA integrity due to 
DNase treatment is negligible and sample quality is enough for array analysis. 
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Table 3.1. Concentration and quality indicators of replicates after DNase treatment. 260/280 and 260/230 
ratios also RINs show RNA of good quality. 
 
Sample name Concentration 260/280 260/230 RIN 
JNN1 183,78 1,89 1,73 9,4 
JNN2 194,63 1,85 1,77 9,8 
JNN3 178,81 1,79 1,8 8 
JAN1 272,6 1,91 1,96 10 
JAN2 168 1,81 1,97 9,8 
JAN3 127,4 1,87 2,16 8,6 
JAP1 169,2 1,92 1,82 10 
JAP2 192,9 1,88 1,82 N/A 
JAP3 164,4 1,78 1,84 8,8 
 
a) 
 
  
ee 
 
 
 
b) 
 
 
 
 
 
Figure 3.8. Bioanalyzer electrpherograms of a) non-treated and b) DNase-treated samples of each 
fraction. 
 
 
3.5. MicroRNA Array Analysis 
 
microRNA expression profiles of camptothecin-treated and non-treated cells 
were compared due to expression changes (1,8-fold change cutoff). 866 miRNAs were 
screened. 37 miRNAs were downregulated whereas 58 miRNAs were upregulated. 
Examples of profiled miRNAs screened in the literature are shown in Table 3.2. These 
Negative control negative fraction
RIN: 10 RIN: 10 RIN: 9,6
Camptothecin-treated negative fraction Camptothecin-treated positive fraction
Negative control negative fraction
RIN: 9.6 RIN: 9.6 RIN: 8.5
Camptothecin-treated negative fraction Camptothecin-treated positive fraction
  21
miRNAs are supposed to have regulatory role in cancer, cell cycle regulation, also have 
predicted targets in apoptosis machinery. There are also miRNAs without known 
function based on the literature. After determination of candidate miRNAs based on 
literature screening and verification by quantitative PCR, further characterization will 
be accomplished knock-down and overexpression studies. 
 
Table 3.2. Representative list of miRNAs as a result of array analysis. These miRNAs are supposed to 
have role in cell cycle regulation, tumour formation and have predicted targets in apoptosis 
machinery. Some of them have no known function in the literature. 
 
miRNA name Up/down 
regulation 
Fold 
Change 
Known Function 
miR-18b Down-
regulated 
8,2 miR-18b has the potential to regulate multiple 
antiapoptotic genes, including Akt, Sp1, Bcl-2, E2F, 
and IGF1 (Wang et al. 2008) 
miR-185 Down-
regulated 
7 miR-185 up-regulation is common in both kidney and 
bladder cancers (Gottardo et al. 2007) 
miR-17, 18a, 20a, 
19b 
Down-
regulated 
3 Members of the miR17-92 cluster. Upregulation 
associated with MYC family which regulate expression 
of cell cycle transcription factor gene E2F1 resulting in 
tumour development (Takakura et al. 2008) 
miR-634 Up-regulated 6 No known function 
miR-1909 Up-regulated 6 No known function 
miR-663 Up-regulated 5,4 Aberrant hypermethylation was shown for mir-663 in 
34–86% of cases in 71 primary human breast cancer 
specimens where tumour suppressor genes are 
inactivated by aberrant hypermethylation (Lehmann et 
al. 2007) 
miR-133a Up-regulated 4 Targeting transcript of pyruvate kinase type M2 
(PKM2), a potential oncogene in solid cancers. 
Overexpression of PKM2 in the cancer cells was partly 
caused by downregulation of miR-133a. It can also 
modulate the intrinsic apoptotic machinery as observed 
in tongue cancer cell lines (Wong et al. 2008) 
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